[Lymphokine production in vitro by blood lymphocytes from patients with a defective or hyperactive immune system].
Blood lymphocytes from 8 patients with common variable immunodeficiency (CVID), 5 patients with signs of polyclonal activation of the immune system (1 SLE, 3 AILAP, 1 NHL) and 6 patients with various granulomatous diseases were examined for their capacity to produce lymphokines in vitro. Lymphocytes from 16 healthy individuals served as controls. To induce interleukin-2 (IL-2) and gamma-interferon (gamma-IFN) production lymphocytes were stimulated for 24 hrs with ConA or PHA or for 72 hrs with ConA + PMA + urea. alpha-IFN production was induced with Herpes simplex virus I (HSV) and the mycoplasma infected murine leukemia line L1210. Cell-free culture supernatants were harvested and IL-2 activity was determined by means of its growth promoting activity for a murine T-cell line (M-2). IFN activities were measured in a conventional virus plaque reduction assay. Besides lymphokine production the isolated cells were also examined for lymphocyte markers, mitogen responsiveness and NK activity. As compared to the control group, CVID lymphocytes exhibited a slightly enhanced IFN production and a moderately reduced IL-2 production. Three day preincubation in FCS containing medium enhanced the IL-2 production of control and patient lymphocytes. By contrast, preincubation of lymphocytes in medium supplemented with autologous serum no longer enhanced IL-2 production of CVID lymphocytes whereas it still did so for control lymphocytes. A striking finding was the impairment of IL-2 and IFN production in cultures of lymphocytes from patients with a polyclonally activated immune system. Notably lymphocytes from the three patients with angioimmunoblastic lymphadenopathy (AILAP) failed to produce significant amounts of lymphokines. Patients with granulomatous diseases (3 Morbus Behçet, 1 tuberculosis, 2 chronic granulomatous diseases) showed little alterations of their lymphokine production capacity. The results are compared with other lymphocyte parameters and are discussed in view of recent reports in the literature on lymphokine production in various diseases.
D000328:Adult; D000936:Antigen-Antibody Complex / Q000032:analysis; D002478:Cells, Cultured; D003166:Complement Activating Enzymes / Q000032:analysis; D015922:Complement C1q; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007153:Immunologic Deficiency Syndromes / Q000276:immunology*; D007372:Interferons / Q000502:physiology; D007376:Interleukin-2 / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology*; D008222:Lymphokines / Q000096:biosynthesis*; D008232:Lymphoproliferative Disorders / Q000276:immunology*; D008297:Male; D008875:Middle Aged
D000936:Antigen-Antibody Complex; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007376:Interleukin-2; D008222:Lymphokines; D015922:Complement C1q; D007372:Interferons; D003166:Complement Activating Enzymes
Lymphokinproduktion in vitro durch Blutlymphozyten von Patienten mit defektem oder hyperreaktivem Immunsystem.